Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS
The National Center for Advancing Translational Sciences, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this Notice to Modala Bio, Inc. (Modala), headquartered in Delaware.
Related coverage
- Agency Information Collection Activities; Court-Ordered Refunds Under the International Emergency Economic Powers Act Worksheet
- Notice To Reestablish the Transit Advisory Committee for Safety Charter
- Potential Designations of the Investment Banking Representative License (Series 79) and the Research Analyst License (Series 86 and Series 87) as Qualifying Natural Persons for Accredited Investor Status
- Potential Designation of U.S. Certified Public Accountant License as Qualifying Natural Persons for Accredited Investor Status
- Potential Designation of Certified Financial Planner Certification as Qualifying Natural Persons for Accredited Investor Status
- Potential Designation of Passage of an Accredited Investor Exam To Be Developed by FINRA as Qualifying Natural Persons for Accredited Investor Status